Agnes Ang

TL;DR: Sotorasib showed anticancer activity in patients with KRAS p.G12C-mutated advanced solid tumors in a phase 1 study as discussed by the authors, and particularly promising anti-cancer activity was observed i...

TL;DR: This multicentre, randomised, double-blind, placebo-controlled, phase 3 study aimed to assess the efficacy, safety, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine, and to assess potential biomarkers, in patients with advanced MET-positive gastric or gastro-oesophageal junction adenocarcinoma.

TL;DR: In this paper, the authors evaluated matched pre-treatment and post-treatment specimens from 43 patients treated with the KRAS(G12C) inhibitor sotorasib and observed multiple treatment-emergent alterations across 27 patients, including alterations in KRAS, NRAS, BRAF, EGFR, FGFR2, MYC and other genes.

TL;DR: Pharmacokinetic data support U3-1287 dosing of 9 to 20 mg/kg every 2 to 3 weeks, and some evidence of disease stabilization was observed, in patients with advanced solid tumor.

TL;DR: Although patients with baseline ctDNA RAS mutations had worse outcomes than patients who were WT RAS before initiating treatment, emergent ct DNA RAS mutation were not associated with less favorable patient outcomes in panitumumab-treated patients.